Previous 10 | Next 10 |
home / stock / cslly / cslly news
2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment PR Newswire Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia 1 This year, the ...
2023-11-17 16:38:12 ET Summary CSL Limited might possibly embark on a new share buyback plan in the future, when its financial leverage ratio is reduced. CSL Limited is committed to allocating 10%-11% of its sales to R&D investments on a yearly basis, and this is supportive of...
CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire HEMGENIX ® , the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass. , Oct. 27,...
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B Canada NewsWire CSL's HEMGENIX ® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON ...
2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...
2023-10-13 16:37:00 ET Summary Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands Haemonetics' Hospital product portfolio; a specialty guide...
New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines PR Newswire Data evaluating the impact of cell-based quadrivalent influenza vaccines suggests an additional 31%–39% of in...
2023-10-05 15:26:42 ET More on GSK GSK: Strong Positioning And Trading At Historical Discount Merck Vs. GSK: The Game-Changer Race In Pharma Excellence GSK plc (GSK) BofA Global Healthcare Conference (Transcript) GSK to trim Haleon stake in over $1B share sal...
2023-10-05 07:59:37 ET More on uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure: The AMT-130 Readout uniQure cleared to start U.S. trial for gene therapy Seeking Alpha’s Quant Rating on uniQure Historical earnings data for u...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These res...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...